All News
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
A Polygenic Model for Still's Disease
Adult-onset Still's disease (AOSD) is systemic autoinflammatory disorder of unknown etiology. It is considered among the febrile autoinflammatory etiologies.
Biosimilar Slow Growth in USA
A recent Forbes article, "Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy Ride", reviews the current state and reasons for slowish uptake of these significant cost-savings alternatives to biologic therapy in treating cancer and autoimmune disorders. The following are takeaway bullets from this informative article.
Read Article
Advances in the treatment of autoimmune hepatitis
Autoimmune hepatitis (AIH) is a chronic, progressive liver disease caused by immune system dysregulation that targets the liver. If untreated, AIH can lead to severe complications, including cirrhosis and liver failure.
Read Article
Iberdomide Efficacy in Cutaneous Lupus
Iberdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).
Read Article
GLP-1 Inhibitor Reduces Knee Osteoarthritis Pain
Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a randomized trial showed.
Read Article
Filgotinib Efficacy and Safety - 3 Years Later
Filgotinib, the rheumatoid arthritis (RA) oral drug that never made it to the U.S. market but is sold across Europe, Great Britain, and Japan, remained effective for 3 years for most registration trial participants who continued in a long-term extension study, researchers said.
Read Article
Swapping is Better than Cycling in Psoriatic Arthritis
A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor, rather than cycling to another TNFi.
Read Article
Potential OA Treatment - Chemokine CCL17 Inhibition
Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.
Read Article
Long-term Tofacitinib in Juvenile Idiopathic Arthritis
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA
Predictors of Adverse Pregnancy Outcomes in Lupus
Pain Relief in RA: JAK Better than TNF Inhibitors?
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
Read Article